MEDPACE



Q2 2018 Financial Results

July 30, 2018

Forward Looking Statements & Non-GAAP Financial Measures

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our anticipated financial results and effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "seek," "seek," "seek," "forecast," "may," "could," "likely," "anticipate," "goal," "objective," similar expressions, and variations or negatives of these words.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following; the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate; fluctuation in our results between fiscal guarters and years; decreased operating margins due to increased pricing pressure or other pressures; failure to perform our services in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; our failure to successfully execute our growth strategies; the impact of a failure to retain key executives or other personnel or recruit experienced personnel; the risks associated with our information systems infrastructure, including potential security breaches and other disruptions which could compromise our information; our failure to manage our growth effectively; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; the risks associated with our intercompany pricing policies; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services; the risks related to our Phase I clinical services; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; the risks related to our relationships with existing or potential customers who are in competition with each other; our failure to successfully integrate potential future acquisitions; potential impairment of goodwill or other intangible assets; our limited ability to utilize our net operating loss carryforwards or other tax attributes; the risks associated with the use and disposal of hazardous substances and waste; the failure of third parties to provide us critical support services; our limited ability to protect our intellectual property rights; the risks associated with potential future investments in our customers' business or drugs; general economic conditions in the markets in which we operate, including financial market conditions; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of recent consolidation in the biopharmaceutical industry: failure to comply with federal, state and foreign healthcare laws: the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of or withdraw an approved drug, biologic or medical device from the market; failure to keep pace with rapid technological changes; the impact of industry-wide reputational harm to CROs; the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.'s exit from the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU; changes in U.S. generally accepted accounting principles, including the impact of the changes to the revenue recognition standards; risks related to internal control over financial reporting; our ability to fulfill our debt obligations; the risks associated with incurring additional debt or undertaking additional debt obligations; the effect of covenant restrictions under our debt agreements on our ability to operate our business; our inability to generate sufficient cash to service all of our indebtedness; fluctuations in interest rates; and our dependence on our lenders, which may not be able to fund borrowings under the credit commitments, and our inability to borrow.

These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 27, 2018, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. These factors should not be construed as exhaustive and should be read in conjunction with the Other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management's estimates as of the date of this presentation. We cannot guarantee that any forward-looking statements ment will be read in accurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. While we may elect to update subsequent to the date subsequent to the date subsequent to the date subsequent to the date of this presentation.

Non-GAAP Financial Measures

Certain financial measures presented in this presentation, such as EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income (including Adjusted Net Income per diluted share) and Free Cash Flow, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA, Adjusted EBITDA, Adj

We believe that EBITDA, Adjusted EBITDA and Adjusted EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income (loss) attributable to Medpace Holdings, Inc. before income tax expense, net, depreciation and adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA, adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA, adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA, and Adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA, and Adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA, and Adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA and Adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, Adjusted EBITDA and Adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, adjusted EBITDA by Service revenue, net for each period. Our presentation of EBITDA, adjusted EBITDA by Service revenue, net for each period.

We utilize Free Cash Flow as a measure of profitability and an assessment of our ability to generate cash. Free Cash Flow is a commonly utilized metric that companies provide to investors, although the calculation of Free Cash Flow may not be comparable to other similarly titled metrics of other companies and should not be considered as an alternative to cash flow measures derived in accordance with U.S. GAAP. We define Free Cash Flow as net cash provided by operating activities, less capital expenditures and the principal portion of payments related to campus leases classified for accounting purposes as deemed landlord liabilities.

Adjusted Net Income (including Adjusted Net Income per diluted share) measures our operating performance by adjusting net income (loss) attributable to Medpace Holdings, Inc. to include cash expenditures related to rental payments on leases classified for accounting purposes as deemed landlord liabilities, and exclude amortization expense, certain stock based compensation award non-cash expenses, certain litigation expenses, deferred financing fees and certain other non-recurring items such Management uses this measure to evaluate our core operating results as it excludes certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operating results as it excludes certain items such as depreciation, interest expense and tax expense, which are otherwise excluded from Adjusted EBITDA. We believe the presentation of Adjusted Net Income (including Adjusted Net Income per diluted share) enhances our investors' overall understanding of the financial performance and cash flow of our business. You should not consider Adjusted Net Income (including Adjusted Net Income (loss) attributable to Medpace Holdings Inc., determined in accordance with U.S. GAAP, as an indicator of operating performance.

EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income (including Adjusted Net Income per diluted share) and Free Cash Flow have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the consolidated financial statements included elsewhere in this prospectus for our U.S. GAAP results. Additionally, for reconciliations of EBITDA, Adjusted EBITDA, Adjusted Net Income (including Adjusted Net Income (and Closest reported U.S. GAAP measures, refer to the appendix of this presentation.


Q2 2018 – Key Operating Highlights

(\$ in millions)	ASC 606		ASC 605		ASC 606	ASC 605					
	2Q18	2Q18	2Q17	% Change	YTD18	YTD18	YTD17	% Change			
Revenue, net	\$170.1				\$333.2						
Service Revenue, net		\$117.8	\$94.6	24.6%		\$226.2	\$188.3	20.1%			
Net New Business Awards	239.9	155.9	105.4	47.9%	440.7	284.1	199.2	42.6%			
Net Book-to-Bill ^(A)	1.41	1.32	1.11	n.m.	1.32	1.26	1.06	n.m.			
Net Book-to-Bill (LTM) (B)		1.20	1.08	n.m.							
Ending Backlog	\$979.7	\$583.6	\$495.9	17.7%							
Backlog Conversion Rate (C)	18.7%	21.5%	19.5%	n.m.	18.7%	21.1%	19.5%	n.m.			
Active Headcount	2,661	2,661	2,482	7.2%							

А. В.

Net Book-to-Bill: Net New Business Awards divided by Revenue, net under ASC 606 and Service Revenue, net under ASC 605. Net Book-to-Bill (LTM) is not applicable under ASC 606. Backlog Conversion Rate: Revenue, net, for the quarter divided by beginning backlog under ASC 606. Service Revenue, net, for the quarter divided by beginning backlog under ASC 605. Year-to-date backlog conversion figures represent the average backlog for all quarters. C.

Backlog and New Award Trends



MEDPACE


Q2 2018 – Key Financial Highlights

(\$ in millions, except per share data)	ASC 606		ASC 605		ASC 606		ASC 605	
	2Q18	2Q18	2Q17	% Change ^(B)	YTD18	YTD18	YTD17	% Change ^(B)
Revenue, net	\$ 170.1				\$ 333.2			
Service Revenue, net		\$ 117.8	\$ 94.6	24.6%		\$ 226.2	\$ 188.3	20.1%
EBITDA ^(A)	33.4	36.3	27.7	30.9%	63.1	68.2	54.9	24.3%
Adj. EBITDA ^(A)	32.9	35.8	26.8	33.6%	61.7	66.8	53.0	26.0%
% Margin	19.4%	30.4%	28.3%	n.m.	18.5%	29.5%	28.1%	n.m.
Adj. Net Income ^(A)	22.4	24.6	15.5	58.9%	42.4	46.3	29.8	55.5%
Adj. Net Income per diluted share ^(A)	\$0.61	\$0.67	\$0.38	76.3%	\$1.16	\$1.27	\$0.72	76.4%


A. See the appendix for the non-GAAP reconciliation of the EBITDA, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per diluted share calculations.
 B. On a constant currency basis, in the second quarter of 2018 net service revenue increased 24.0%, EBITDA increased 31.0%, and Adjusted EBITDA increased 33.7%.

On a constant currency basis, in the second quarter of 2010 het service revenue increased 19.1%, EBITDA increased 26.1%, and Adjusted EBITDA increased 27.8%. Note: Adjusted Net Income is reflective of an estimated effective tax rate of 23% for 2Q18 and year-to-date 2018 and an estimated effective tax rate of 36% for 2Q17 and year-to-date 2017.

Key Financial Trends



(\$ in millions) Adjusted Net Income^(B)



Represents percent of Revenue, net (under ASC 606)

Adjusted Net Income per diluted share^(B)




Α. Represents Revenue, net under ASC 606 and Service Revenue, net under ASC 605.

See the appendix for the non-GAAP reconciliation of the Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per diluted share calculations. В. Note: Adjusted Net Income is reflective of an estimated effective tax rate of 23% for 2Q18 and an estimated effective tax rate of 36% for 2Q17.

\$35.8

YTD 2018- Revenue Composition under ASC 606



- A. Other primarily includes Nephrology, Rheumatology, Musculoskeletal, Dermatology, Gastroenterology, and Ophthalmology therapeutic areas.
 B. Current period customer tiers classified by Evaluate Ltd. in EvaluatePharma© World Preview 2018 Outlook to 2024 as well as management analysis. Large Pharma represents the top 20 pharma companies worldwide based on annual sales as of 12/31/17. Mid-sized biopharma represents customers with >\$250M of annual sales as of 12/31/17. Small Biopharma represents customers with <\$250M of annual sales as of 12/31/17.
- C. No single customer represents over 10% of revenue.

Leverage Position and Cash Flow

		(\$ in millions)	orogo(A) Tre	end (Quarter	(ha)	(\$ in millions)	ASC 606	ASC	605	ASC 606	ASC	605
		Net Lev	erage ^w rre	ena (Quarter	iy <i>)</i>	Free Cash Flow	2Q18	2Q18	2Q17	YTD18	YTD18	YTD17
		Adjusted E	BITDA (LTM)	Net Levera	^{ge} \$121.8	Operating Cash Flow (GAAP)	\$ 41.3	\$ 41.3	\$30.4	\$ 64.6	\$ 64.6	\$29.7
		\$108.5	\$108.0	\$112.8		Less: CAPEX	5.8	5.8	1.6	9.8	9.8	6.0
		1.5x	1.8x	1.6x	1.2x	Less: Campus Lease ^(G)	0.5	0.5	0.4	0.9	0.9	0.8
		3Q17	4Q17	1Q18	2Q18	Free Cash Flow (non-GAAP)	\$ 35.0	\$ 35.0	\$28.4	\$ 53.9	\$ 53.9	\$22.9
Term Lo	oan	\$155.7	\$152.6	\$148.5	\$144.4	, , ,						
Revolve	er	\$30.0	\$70.0	\$50.0	\$20.0	Adj. EBITDA (non-GAAP)	\$ 32.9	\$ 35.8	\$26.8	\$ 61.7	\$ 66.8	\$53.0
Gross [Debt ^(B)	\$185.7	\$222.6	\$198.5	\$164.4							
Cash ^(C))	24.2	26.5	22.2	22.2	Free Cash Flow Conversion % ^(H)	106.4%	97.9%	105.9%	87.5%	80.8%	43.2%
Net Del	bt ^(D)	\$161.5	\$196.1	\$176.3	\$142.1	(non-GAAP)						
Net	ASC 605	^(E) 5.3	7.6	8.7	4.1							
DSO	ASC 606	(F)		(0.1)	(3.0)							

Net Leverage defined as Net Debt divided by LTM Adjusted EBITDA under ASC 605. Α.

В. С. Gross debt is defined as Long-term Debt, including the current portion of Long-term Debt and the revolving credit facility balance, excluding unamortized discounts and unamortized debt issuance costs.

Cash is defined as Cash and Cash Equivalents.

Ď. Net Debt, a non-GAAP financial measure, is defined as Gross Debt less Cash.

ASC 605 Net Days Sales Outstanding (DSO) reflects Service Revenue, net, as reported under ASC 605, and is based on billed and unbilled Accounts receivable, net of Advanced billings, including Ε. Reimbursed out-of-pocket revenue and expenses.

F. ASC 606 Net Days Sales Outstanding (DSO) reflects Revenue, net, as reported under ASC 606, and is based on billed and unbilled Accounts receivable, net of Advanced billings, including Reimbursed out-of-pocket revenue and expenses. Represents principal portion of Corporate Campus Lease payment. Free Cash Flow Conversion % is equal to Free Cash Flow divided by Adjusted EBITDA. G.

Η.

Full Year 2018 Guidance under ASC 605

(\$ in millions, except per share data)	Previous G (April 30		\$461.0 - \$473.0 19.3% \$135.0 - \$141.0 25.0% \$92.0 - \$96.0 52.2% \$2.51 - \$2.62 65.1%	
	Guidance Range	Growth Rate ^(A)	Guidance Range	Growth Rate ^(A)
Service Revenue, net	\$421.0 - \$435.0	8.9% - 12.6%	\$461.0 - \$473.0	19.3% - 22.4%
Adjusted EBITDA	\$105.0 - \$111.0	(2.8%) – 2.7%	\$135.0 - \$141.0	25.0% – 30.5%
Adjusted Net Income	\$68.0 - \$72.0	12.5% – 19.1%	\$92.0 - \$96.0	52.2% – 58.8%
Adjusted Net Income per diluted share	\$1.87 - \$1.97	22.7% – 29.9%	\$2.51 - \$2.62	65.1% – 72.3%
GAAP Net Income	\$46.2 - \$50.4	18.1% – 28.8%	\$69.8 - \$73.9	78.4% – 88.9%
GAAP Net Income per diluted share	\$1.27 - \$1.38	29.6% – 40.8%	\$1.90 - \$2.01	93.7% – 104.9%

A. Growth rates are based on 2017 adjusted figures, with the exception of Service Revenue, net. See appendix for detailed reconciliation of results. *Note: Full Year 2018 guidance does not reflect ASC 606 implementation.*

Appendix



Q2 2018 – Income Statement

		18					2Q18		2Q17			2Q18 vs	
		ported	% Revenue,				Revised	% Service	As Reported	% Service		under A	
(\$ in millions, except per share amounts)	under A	ASC 606	net	Adj	ustments	unde	r ASC 605	Revenue, net	under ASC 605	Revenue, net	\$ C	Change	% Change
Revenue:													
Revenue, net	\$	170.1	100.0%	\$	(170.1)	\$	-	-	\$-	-	\$	-	n.r
Service revenue, net		-	-		117.8		117.8	100.0%	94.6	100.0%		23.2	24.6%
Reimbursed out-of-pocket revenue		-	-		19.0		19.0		11.7				
Total revenue		170.1	100.0%		(33.3)		136.8		106.2	·			
Operating Expenses:													
Direct service costs, excluding depreciation and amortization		61.5	36.1%		-		61.5	52.2%	52.0	54.9%		9.5	18.3%
Reimbursed out-of-pocket expenses		55.2	32.4%		(36.2)		19.0	16.2%	11.7	12.3%			
Total direct costs		116.7	68.6%		(36.2)		80.5	68.4%	63.6	67.3%		16.9	26.6%
Selling, general and administrative		20.5	12.1%		-		20.5	17.4%	14.8	15.6%		5.8	39.0%
Depreciation		2.2	1.3%		-		2.2	1.9%	2.1	2.2%		0.1	5.9%
Amortization		7.4	4.3%		-		7.4	6.3%	9.5	10.0%		(2.1)	(21.9%
Total operating expenses		146.8	86.3%		(36.2)		110.6	93.9%	89.9	95.1%		20.7	23.0%
Income from operations		23.3	13.7%		2.8	<u> </u>	26.2	22.2%	16.3	17.2%		9.9	
Other expense, net:													
Miscellaneous income (expense), net		0.5	0.3%		-		0.5	0.4%	(0.1)	(0.1%)		0.6	
Interest expense, net		(2.3)	(1.4%)		-		(2.3)	(2.0%)	(1.8)	(1.9%)		(0.5)	
Total other expense, net		(1.8)	(1.1%)		-		(1.8)	(1.6%)	(1.9)	(2.0%)	_	0.1	
Income before income taxes		21.5	12.6%		2.8		24.4	20.7%	14.3	15.2%		10.0	
Income tax provision		4.9	2.9%		0.7		5.6	4.8%	4.8	5.1%		0.8	
Net income	\$	16.6	9.7%	\$	2.2	\$	18.8	15.9%	\$ 9.6	10.1%	\$	9.2	
Basic EPS (GAAP)	\$	0.46		\$	0.07	\$	0.53		\$ 0.24		\$	0.29	120.8%
Diluted EPS (GAAP)	\$	0.45		\$	0.06	\$	0.51		\$ 0.23		\$	0.28	121.7%
Basic EPS (Adi.)	\$	0.63		\$	0.06	\$	0.69		\$ 0.38		\$	0.31	81.6%
Diluted EPS (Adj.)	\$	0.61		\$	0.06	\$	0.67		\$ 0.38		\$	0.29	76.3%
EBITDA	\$	33.4		\$	2.8	\$	36.3		\$ 27.7		\$	8.6	30.9%
EBITDA Margin	Ψ	19.7%		Ŷ	2.0	Ψ	30.8%		29.3%		Ψ	1.5%	00.07
Adjusted EBITDA	\$	32.9		\$	2.8	\$	35.8		\$ 26.8		\$	9.0	33.6%
Adjusted EBITDA - Margin		19.4%					30.4%		28.3%			2.1%	

Reconciliation of Adjusted EBITDA

		ASC	C 606		ASC	605		AS	SC 606		ASC	605		_	ASC	605	
(\$ in millions)		20	2Q18		2Q18		2Q17	Y	TD18	Y	TD18	١	/TD17	LT	M 2018	LT	M 2017
Net income as reported (GAAP)		\$	16.6	\$	18.8	\$	9.6	\$	31.1	\$	35.1	\$	18.0	\$	56.2	\$	23.0
Income tax provision			4.9		5.6		4.8		8.1		9.2		10.1		16.9		12.9
Interest expense, net			2.3		2.3		1.8		4.6		4.6		3.6		8.6		11.1
Depreciation			2.2		2.2		2.1		4.5		4.5		4.2		8.9		8.1
Amortization			7.4		7.4		9.5		14.8		14.8		18.9		33.8		44.2
EBITDA (non-GAAP)		\$	33.4	\$	36.3	\$	27.7	\$	63.1	\$	68.2	\$	54.9	\$	124.3	\$	99.4
Adjustments to EBITDA:																	
Corporate campus lease payments	(A)		(1.0)		(1.0)		(0.9)		(1.9)		(1.9)		(1.9)		(3.8)		(3.7
Stock compensation expense: liability awards mark-to-market	(B)		-		-		-		-		-		-		-		3.1
Other transaction expenses	(C)		0.4		0.4		-		0.4		0.4		-		1.3		0.5
Loss on extinguishment of debt	(D)		-		-		-		-		-		-		-		10.7
Adjusted EBITDA - (non-GAAP)		\$	32.9	\$	35.8	\$	26.8	\$	61.7	\$	66.8	\$	53.0	\$	121.8	\$	109.9
Net income margin (GAAP)			9.7%		15.9%		10.1%		9.3%		15.5%		9.6%				
Adjusted EBITDA margin (non-GAAP)			19.4%		30.4%		28.3%		18.5%		29.5%		28.1%				

A. Represents cash rental payments on two corporate headquarter buildings that are accounted for as deemed assets and subject to depreciation expense over the life of the lease. Payments made for these leases are accounted for with a principal portion and an interest portion, consistent with deemed landlord liability accounting. These adjustments for purposes of arriving at Adjusted EBITDA have the effect of presenting these leases consistently with all other office lease rentals that we have globally.

B. Represents period end mark-to-market fair value adjustments associated with liability classified awards. Future stock based awards activity is expected to be classified as equity for accounting purposes and will not be subject to period ending fair value adjustments.

C. Represents advisory costs and other fees incurred in connection with the August 2016 initial public offering, the 2017 S-3 registration statement, and follow-on offerings.

D. Represents a loss on extinguishment of long-term debt in connection with the repayment and extinguishment of our obligations under the previous Senior Secured Credit Facilities during the fourth quarter of 2016.

Reconciliation of Adjusted Net Income

		ASC 606			AS	C 605		A	SC 606	ASC 605				
(\$ in millions)			2Q18		2Q18	2Q17		١	/TD18	Ŷ	′TD18	YTD17		
Net income as reported (GAAP)		\$	16.6	\$	18.8	\$	9.6	\$	31.1	\$	35.1	\$	18.0	
Amortization			7.4		7.4		9.5		14.8		14.8		18.9	
Corporate campus lease payments-principal portion	(A)		(0.5)		(0.5)		(0.4)		(0.9)		(0.9)		(0.8	
Deferred financing fees	(B)		0.2		0.2		0.2		0.3		0.3		0.3	
Other transaction expenses	(C)		0.4		0.4		-		0.4		0.4			
Income tax effect of adjustments	(D)		(1.7)		(1.7)		(3.3)		(3.4)		(3.4)		(6.6)	
Adjusted Net Income (non-GAAP)		\$	22.4	\$	24.6	\$	15.5	\$	42.4	\$	46.3	\$	29.8	

- A. Represents cash rental payments on two corporate headquarter buildings that are accounted for as deemed assets and subject to depreciation expense over the life of the lease. Payments made for these leases are accounted for with a principal portion and an interest portion, consistent with deemed landlord liability accounting. These adjustments for purposes of arriving at Adjusted Net Income have the effect of presenting these leases consistently with all other office lease rentals that we have globally.
- B. Represents amortization of the discount and issuance costs deferred on the consolidated balance sheet associated with the issuance of the Senior Secured Credit Facility.
- C. Represents advisory costs and other fees incurred in connection with the 2017 S-3 registration statement and follow-on offerings.
- D. Represents the tax effect of the total adjustments at an estimated effective tax rate of 36% for 2Q17 and year-to-date 2017 and an estimated tax rate of 23% for 2Q18 and year-to-date 2018.

Adjusted EBITDA Reconciliation Trends

					ASC	605				ASC	606
(\$ in millions)		3Q16	4Q16	1Q17	2Q17	3Q17	4Q17	1Q18	2Q18	1Q18	2Q18
Net income (loss) as reported (GAAP)		\$ 5.0	\$(-)	\$ 8.4	\$ 9.6	\$ 9.8	\$ 11.3	\$ 16.3	\$ 18.8	\$ 14.6	\$ 16.6
Income tax provision		2.5	0.2	5.3	4.8	5.3	2.4	3.6	5.6	3.1	4.9
Interest expense, net		4.7	2.8	1.8	1.8	1.9	2.1	2.3	2.3	2.3	2.3
Depreciation		1.9	2.0	2.1	2.1	2.2	2.1	2.3	2.2	2.3	2.2
Amortization		12.7	12.7	9.4	9.5	9.5	9.5	7.4	7.4	7.4	7.4
EBITDA (non-GAAP)		\$ 26.8	\$ 17.7	\$ 27.2	\$ 27.7	\$ 28.8	\$ 27.3	\$ 31.9	\$ 36.3	\$ 29.7	\$ 33.4
Adjustments to EBITDA:											
Corporate campus lease payments	(A)	(0.9)	(0.9)	(0.9)	(0.9)	(0.9)	(1.0)	(1.0)	(1.0)	(1.0)	(1.0
Stock compensation expense: liability awards mark-to-market	(B)	3.1	-	-	-	-	-	-	-	-	
Other transaction expenses	(C)	0.5	-	-	-	0.2	0.6	-	0.4	-	0.4
Loss on extinguishment of debt	(D)	-	10.7	-	-	-	-	-	-	-	
Adjusted EBITDA (non-GAAP)		\$ 29.5	\$ 27.5	\$ 26.2	\$ 26.8	\$ 28.0	\$ 27.0	\$ 31.0	\$ 35.8	\$ 28.7	\$ 32.9

A. Represents cash rental payments on two corporate headquarter buildings that are accounted for as deemed assets and subject to depreciation expense over the life of the lease. Payments made for these leases are accounted for with a principal portion and an interest portion, consistent with deemed landlord liability accounting. These adjustments for purposes of arriving at Adjusted EBITDA have the effect of presenting these leases consistently with all other office lease rentals that we have globally.

B. Represents period end mark-to-market fair value adjustments associated with liability classified awards. Future stock based awards activity is expected to be classified as equity for accounting purposes and will not be subject to period ending fair value adjustments.

C. Represents advisory costs and other fees incurred in connection with the August 2016 initial public offering, the 2017 S-3 registration statement, and follow-on offerings.

D. Represents a loss on extinguishment of long-term debt in connection with the repayment and extinguishment of our obligations under the previous Senior Secured Credit Facilities during the fourth quarter of 2016.

Adjusted Net Income Reconciliation Trends

					ASC	605				ASC	; 606
(\$ in millions, expect per share amounts)		3Q16	4Q16	1Q17	2Q17	3Q17	4Q17	1Q18	2Q18	1Q18	2Q18
Net income (loss) as reported (GAAP)		\$ 5.0	\$(-)	\$ 8.4	\$ 9.6	\$ 9.8	\$ 11.3	\$ 16.3	\$ 18.8	\$ 14.6	\$ 16.6
Amortization		12.7	12.7	9.4	9.5	9.5	9.5	7.4	7.4	7.4	7.4
Stock based compensation expense: liability awards mark-to-market	(A)	3.1	-	-	-	-	-	-	-	-	-
Corporate campus lease payments-principal portion	(B)	(0.4)	(0.4)	(0.4)	(0.4)	(0.4)	(0.4)	(0.5)	(0.5)	(0.5)	(0.5)
Deferred financing fees	(C)	0.7	0.6	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Other transaction expenses	(D)	0.5	-	-	-	0.2	0.6	-	0.4	-	0.4
Loss on extinguishment of debt	(E)	-	10.7	-	-	-	-	-	-	-	-
Income tax effect of adjustments	(F)	(6.4)	(9.2)	(3.6)	(3.3)	(3.4)	(3.5)	(1.6)	(1.7)	(1.6)	(1.7)
Tax reform adjustments	(G)	-	-	-	-	-	(2.8)	-	-	-	
Adjusted Net Income (non-GAAP)		\$ 15.1	\$ 14.3	\$ 14.1	\$ 15.5	\$ 15.9	\$ 14.8	\$ 21.8	\$ 24.6	\$ 20.0	\$ 22.4
Net Income (loss) per diluted share (GAAP)		\$ 0.13	\$(-)	\$ 0.20	\$ 0.23	\$ 0.25	\$ 0.30	\$ 0.45	\$ 0.51	\$ 0.40	\$ 0.45
Adjusted Net Income per diluted share (non-GAAP)		\$ 0.40	\$ 0.35	\$ 0.34	\$ 0.38	\$ 0.40	\$ 0.39	\$ 0.60	\$ 0.67	\$ 0.55	\$ 0.61
Diluted weighted average common shares outstanding (GAAP)		37.6	40.7	41.5	40.8	39.3	37.8	36.4	36.7	36.4	36.7
Adjusted diluted weighted average common shares outstanding (non-GAAP)	(H)	37.6	41.4	41.5	40.8	39.3	37.8	36.4	36.7	36.4	36.7

A. Represents period end mark-to-market fair value adjustments associated with liability classified awards. Future stock based awards activity is expected to be classified as equity for accounting purposes and will not be subject to period ending fair value adjustments.

- B. Represents cash rental payments on two corporate headquarter buildings that are accounted for as deemed assets and subject to depreciation expense over the life of the lease. Payments made for these leases are accounted for with a principal portion and an interest portion, consistent with deemed landlord liability accounting. These adjustments for purposes of arriving at Adjusted Net Income have the effect of presenting these leases consistently with all other office lease rentals that we have globally.
- C. Represents amortization of the discount and issuance costs deferred on the consolidated balance sheet associated with the issuance of the Senior Secured Credit Facility.
- D. Represents advisory costs and other fees incurred in connection with the August 2016 initial public offering, the 2017 S-3 registration statement, and follow-on offerings.
- E. Represents a loss on extinguishment of long-term debt in connection with the repayment and extinguishment of our obligations under the previous Senior Secured Credit Facilities during the fourth quarter of 2016.
- F. Represents the tax effect of the total adjustments at an estimated effective tax rate of 39% for 3Q16 through 1Q17, an estimated tax rate of 36% for 2Q17 through 4Q17, and an estimated tax rate of 23% for 1Q18 through 2Q18.
- G. Consists of one time adjustments due to U.S. federal tax reform passed in December 2017, including revaluation of deferred credit, partially offset by revaluation of deferred tax assets and deferred tax liabilities, transition tax, and other miscellaneous tax reform related items.
- H. For GAAP purposes, in a period where a net loss is recorded there is no dilution to weighted average common shares outstanding. When considering Adjusted Net Income, however, dilution would be applicable and is considered for purposes of determining Adjusted Net Income per diluted share.

FY2018 Guidance Reconciliation under ASC 605

(\$ in millions, except per share amounts)		Adjusted N	let I	ncome	-	Net Income ted share		
		Low		High	Low		High	
Net Income and Net Income per diluted share (GAAP)		\$ 69.8	\$	73.9	\$ 1.90	\$	2.01	
Adjustments:								
Amortization		29.6		29.6	0.81		0.81	
Other transaction expenses	(A)	0.4		0.4	0.01		0.01	
Corporate campus lease payments - principal portion	(B)	(1.9)		(1.9)	(0.05)		(0.05)	
Deferred financing fees	(C)	0.7		0.7	0.02		0.02	
Income tax effect of adjustments	(D)	 (6.6)		(6.7)	 (0.18)		(0.18)	
Adjusted Net Income and Adjusted Net Income per diluted share (non-GAAP)		\$ 92.0	\$	96.0	\$ 2.51	\$	2.62	
Depreciation		9.4		9.4				
Income tax provision		27.2		29.2				
Interest expense, net		 6.4		6.4				
Adjusted EBITDA (non-GAAP)		\$ 135.0	\$	141.0				

A. Represents advisory costs and other fees incurred in connection with secondary follow-on offerings during 2018.

- B. Represents cash rental payments on two corporate headquarter buildings that are accounted for as deemed assets and subject to depreciation expense over the life of the lease. Payments made for these leases are accounted for with a principal portion and an interest portion, consistent with deemed landlord liability accounting. The interest portion of these payments is included in net cash provided by operating activities in our statement of cash flows. The principal portion is reflected as a financing activity in our statement of cash flows. These adjustments for purposes of arriving at Adjusted EBITDA and Adjusted Net Income (including Adjusted Net Income per diluted share) have the effect of presenting these leases consistently with all other office lease rentals that we have globally.
- C. Represents amortization of the discount and issuance costs deferred on the consolidated balance sheet associated with the issuance of the Senior Secured Credit Facility.
- D. Represents the tax effect of the total adjustments in a range of 22.0% to 25.0%.